COVID Response
EIT Health and MITACs grants have supported this COVID-19 Response collaboration between BioXplor and the University of Manitoba (Haigh Laboratory) to develop an ontology-driven intelligent search engine (100k papers and growing) and a SARS-CoV-2 genome variants browser (100k virus genomes and growing). Both literature and genome tools will be updated with new content continuously throughout the pandemic and are completely open access. These resources have also been applied to support additional research work in variant analysis and drug combinations, more information below. SARS-CoV-2 Genome Variants CovidExplorer

SlideCOVID-19 R&D Discovery Platform PLAY VIDEO

SlideBioXplor has exposed part of it's biomedical knowledge platform to accelerate the discovery of actionable insights from the torrent of COVID-19 literature. The COVID-19 Discovery Engine is completely open-access and supported by COVID-19 response grants, programs & partnerships with EIT Health (European Innovation and Technology Institute), and Creative Destruction Labs. The engine is one of most comprehensive resources for ontology-based knowledge discovery & text mining for COVID-19. It combines structured content from the CORD-19 dataset including PubMed, WHO, Elsevier, PubMed Central, BioRxiv, MedRxiv, using 30+ proprietary biomedical ontology dictionaries to enable scientists to discover insights up to 25X faster than Google Scholar or Pubmed. Open Access Here

SlideBioXplor's platform is being utilized to identify immunomodulation drug targets and drug combinations for COVID-19. The goal is to identify novel treatment combinations for COVID displaying evidence of synergy, safety and efficacy for treatment of high-risk patients with severe disease. Request More Information Case Study - COVID-19 Drug Combinations

SlideAccess Variant Data SARS-CoV-2 Viral Variant Tracker & Primer Design Tool BioXplor is collaborating with the University of Manitoba to develop and distribute a computational platform to track SARS-CoV-2 viral variants in different populations via sequencing data analysis. BioXplor is offering
partnerships to mRNA Vaccine developers and Molecular Diagnostics companies of NGS and RT-PCR test kits for optimal designs to avoid mutational hotspots. In the BioArxiv paper: "early mutational events are described across samples from publicly available SARS CoV-2 sequences from the sequence reads, mostly from China, USA (Washington DC) and Australia 30 (Victoria). 90% of datasets contain at least a single founder mutation and most of the variants are missense (over 63%). Five-point mutations with clonal (founder) effect were found in USA sequencing samples. Australian mutation signatures were more diverse than USA samples."
Access Paper